Table: q1_q4_2023_prescription_drugs_intro_to_market , manufacturer_name like H*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	drug_category	drug_category_source	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Hikma Pharmaceuticals USA Inc	00054962857	Sodium Oxybate Oral Solution 500 MG/ML, 180 ML Bottle	Generic	FDA	2023-01-01	5535.0000	This drug is a generic product; therefore no marketing and pricing plans are available. This product is sold in the United States only.	None	200000	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. Hikma has not evaluated the volume of patients in the USA. Sodium Oxybate oral solution is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age an older with narcolepsy. According to the National Institute of Neurological Disorders and Stroke, approximately 135,000 to 200,000 people in the U.S. have narcolepsy.	None
Hikma Pharmaceuticals USA Inc	00054043825	Levorphanol Tartrate Tablets, 2mg USP, CII, 1 bottle of 100	Generic	FDA	2023-02-02	3337.5000	This drug is a generic product; therefore no marketing and pricing plans are available. This product is sold in the United States only.	None	110000000	None	None	2022-11-30	None	1	Hikma manufactured this product for Sentynl pursuant to a CMO relationship. Hikma, who acquired Roxane, now has re-acquired the ANDA and has transitioned this product back to Hikma owned and Hikma labeling.	Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma has not evaluated the volume of patients in the USA. Levorphanol Tartrate is indicated for the management of pain severe enough to require an opioid analgesic. According to the CDC, 1/3 of the US population have received an opioid prescription, therefore approximately 110,000,000.	None
Hikma Pharmaceuticals USA Inc	00054044949	Posaconazole Oral Suspension, 200mg/5mL, 105mL bottle	Generic	FDA	2023-03-29	1312.8700	This drug is a generic product; therefore no marketing and pricing plans are available. This product is sold in the United States only.	None	25000	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. Hikma has not evaluated the volume of patients in the USA. Posaconazole is indicated for the treatment of oropharyngeal candidiasis. According to the CDC, approximately 25,000 cases of candidemia occur nationwide each year.	None
Hikma Pharmaceuticals USA Inc	00054037025	Lisdexamfetamine Dimesylate Capsules, CII, 20mg, 1 bottle of 100	Generic	FDA	2023-08-25	1052.5500	This drug is a generic product; therefore no marketing and pricing plans are available. This product is sold in the United States only.	None	8700000	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. Hikma has not evaluated the volume of patients in the USA. Lisdexamfetamine dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older and moderate to severe binge eating disorder in adults. According to the Journal of Managed Care and Specialty Pharmacy, an estimated 8.7 million adults live with ADHD in the United States.	None
Hikma Pharmaceuticals USA Inc	00054037125	Lisdexamfetamine Dimesylate Capsules, CII, 30mg, 1 bottle of 100	Generic	FDA	2023-08-25	1052.5500	This drug is a generic product; therefore no marketing and pricing plans are available. This product is sold in the United States only.	None	8700000	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. Hikma has not evaluated the volume of patients in the USA. Lisdexamfetamine dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older and moderate to severe binge eating disorder in adults. According to the Journal of Managed Care and Specialty Pharmacy, an estimated 8.7 million adults live with ADHD in the United States.	None
Hikma Pharmaceuticals USA Inc	00054037225	Lisdexamfetamine Dimesylate Capsules, CII, 40mg, 1 bottle of 100	Generic	FDA	2023-08-25	1052.5500	This drug is a generic product; therefore no marketing and pricing plans are available. This product is sold in the United States only.	None	8700000	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. Hikma has not evaluated the volume of patients in the USA. Lisdexamfetamine dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older and moderate to severe binge eating disorder in adults. According to the Journal of Managed Care and Specialty Pharmacy, an estimated 8.7 million adults live with ADHD in the United States.	None
Hikma Pharmaceuticals USA Inc	00054037325	Lisdexamfetamine Dimesylate Capsules, CII, 50mg, 1 bottle of 100	Generic	FDA	2023-08-25	1052.5500	This drug is a generic product; therefore no marketing and pricing plans are available. This product is sold in the United States only.	None	8700000	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. Hikma has not evaluated the volume of patients in the USA. Lisdexamfetamine dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older and moderate to severe binge eating disorder in adults. According to the Journal of Managed Care and Specialty Pharmacy, an estimated 8.7 million adults live with ADHD in the United States.	None
Hikma Pharmaceuticals USA Inc	00054037425	Lisdexamfetamine Dimesylate Capsules, CII, 60mg, 1 bottle of 100	Generic	FDA	2023-08-25	1052.5500	This drug is a generic product; therefore no marketing and pricing plans are available. This product is sold in the United States only.	None	8700000	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. Hikma has not evaluated the volume of patients in the USA. Lisdexamfetamine dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older and moderate to severe binge eating disorder in adults. According to the Journal of Managed Care and Specialty Pharmacy, an estimated 8.7 million adults live with ADHD in the United States.	None
Hikma Pharmaceuticals USA Inc	00054037525	Lisdexamfetamine Dimesylate Capsules, CII, 70mg, 1 bottle of 100	Generic	FDA	2023-08-25	1052.5500	This drug is a generic product; therefore no marketing and pricing plans are available. This product is sold in the United States only.	None	8700000	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. Hikma has not evaluated the volume of patients in the USA. Lisdexamfetamine dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older and moderate to severe binge eating disorder in adults. According to the Journal of Managed Care and Specialty Pharmacy, an estimated 8.7 million adults live with ADHD in the United States.	None